Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase – positive non‐small cell lung cancer-Reference-Cited by-同舟云学术

Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase – positive non‐small cell lung cancer

Published:2021-09-21 Issue:11 Volume:10 Page:1357-1370
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst Pharmacol

Author:

Hsu Joy C.¹,Jaminion Felix²,Guerini Elena²,Balas Bogdana³,Bordogna Walter³,Morcos Peter N.¹,Frey Nicolas²

Affiliation:

1. Roche Innovation Center F. Hoffmann‐La Roche Ltd New York New York USA

2. Roche Innovation Center F. Hoffmann‐La Roche Ltd Basel Switzerland

3. F. Hoffmann‐La Roche Ltd Basel Switzerland

Funder

Roche

Publisher

Wiley

Subject

Pharmacology (medical),Modelling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12702

Reference33 articles.

1. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

2. Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non–Small Cell Lung Cancer

3. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance

4. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases

5. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia;Lung Cancer: Targets and Therapy;2023-07

2. An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer;Expert Opinion on Pharmacotherapy;2023-06-13

3. Influence of Food With Different Fat Concentrations on Alectinib Exposure: A Randomized Crossover Pharmacokinetic Trial;Journal of the National Comprehensive Cancer Network;2023-06

4. Relative bioavailability and food effect study of an oral suspension of alectinib in healthy volunteers using venipuncture and capillary microsampling;Clinical and Translational Science;2023-04-04

5. Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC);Frontiers in Oncology;2023-03-09